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The main objective of this investigation was to determine the absorption, distribution, excretion, and pharmacokinetics of the
antimalarial drug pyronaridine tetraphosphate (PNDP) in Sprague-Dawley rats. Following oral administration of a single dose
(10mg/Kg) of 14C-PNDP, it was observed that the drug was readily absorbed from the small intestine within 1 hour following
oral administration and was widely distributed in most of the tissues investigated as determined from the observed radioactivity
in the tissues. The peak value of the drug in the blood was reached at around 8 hours postadministration, and radioactivity was
detected in most of the tissues from 4 hours onwards. 14C-PNDP showed a poor permeability across the blood-brain barrier,
and the absorption, distribution, and excretion of 14C-PNDP were found to be gender-independent as both male and female rats
showed a similar pattern of radioactivity. Excretion of the drug was predominantly through the urine with a peak excretion post
24 hours of administration. A small amount of the drug was also excreted in the feces and also in the breath. It was found that
the Cmax, AUC (0-inf), and Tmax values were similar to those observed in the Phase II clinical trials of pyronaridine/artesunate
(Pyramax) conducted in Uganda.
1.Introduction
Malaria, a vector borne infectious disease caused by the pro-
tozoan parasites (Plasmodium) and transmitted to humans
by the female anopheles mosquito, has remained a real and
longstanding cause for concern, mainly in the tropical world.
Malaria has now extended to areas that cover more than
40% of the world’s population and according to the World
health Organisation’s (WHO) latest report there were an
estimated 247 million malaria cases worldwide in 2006, of
which 91% were due to P. falciparum. The vast majority of
cases (86%) were found in the African region, followed by
theSouth-EastAsia(9%)andEasternMediterraneanregions
(3%). Mortality due to malarial infection was estimated to
be about 881,000 deaths worldwide in 2006, of which 90%
were in the African region, and 4% in each of the South-
East Asia and Eastern Mediterranean regions [1]. Several
antimalarial drugs have been developed over the years and
are being used along with antipyretics with varying degree of
success.Chloroquinehaslongbeenthedrugofchoiceagainst
malaria for several years and has been widely employed
in the treatment of falciparum malaria. But the extensive
deployment of the antimalarial drugs, in the past ﬁfty years,
has provided a tremendous impetus for human malaria
parasites to evolve mechanisms of resistance. The discovery
and spread of chloroquine resistant P. falciparum have
highlighted the urgent need for developing new antimalarial
drugs. Presently, resistance has already been reported to all
the antimalarial drug classes except in the case of artemisinin
andthesedrugshavealreadybecomeanessentialcomponent
of treatments for multidrug-resistant falciparum malaria [2].
Theemergenceofresistance,particularlyinP.falciparum,has
been a major contributor to the global resurgence of malaria
in the last three decades. These factors underscore the urgent2 Journal of Biomedicine and Biotechnology
need to identify new antimalarial drugs and to understand
their responses so that appropriate measures can be taken for
their use to delay possible eventual ineﬀectiveness.
According to WHO, artemisinin-based combination
therapy (ACT) is being recommended as the ﬁrst-line treat-
ment for P. falciparum in 66 countries by the end of 2006 and
in almost all countries in the African, South-East Asia, and
Western Paciﬁc regions [3]. ACT has become the mainstay
of antimalarial treatment in most regions where the disease
is endemic [1]. Although, currently available artemisinin
combinations show good eﬃcacy and a sustained high cure,
rates the tolerability, cost, and impaired patient compliance
because of complicated dosing schedules and inappropriate
drug formulations are major drawbacks. Speciﬁc resistance
against drugs currently partnered with artemisinin is rising
and novel partner drugs are therefore currently being devel-
oped to overcome these limitations. A novel ACT Pyramax
(which is a combination of artesunate and pyronaridine
tetraphosphate) is currently under development for the
treatment of uncomplicated falciparum and vivax malaria
under a joint drug development program by the not-for-
proﬁt organization Medicines for Malaria Venture (MMV,
Geneva, Switzerland) and the pharmaceutical company Shin
Poong Pharmaceuticals Co., Ltd. (Seoul, Republic of Korea).
The objective is to provide a ﬁxed dose ACT that has a high
eﬃcacy, good tolerability and safety proﬁle, low cost (less
than $1 per adult-treatment course), long shelf life and an
easy dosing regimen of 1 daily dose over 3 days.
One group of alternative antimalarial drugs that are
being currently considered is the Mannich bases, especially
pyronaridine tetraphosphate (PNDP; Figure 1(a)). It was
ﬁrst synthesized in China and introduced for the treat-
ment of malaria in certain malaria infested regions of
China [4]. Chemically, it is 7-chloro-2-methoxy-10-[3, 5-
bis (pyrolidinyl-1-methyl)-4-hydroxyanilino] benzo [b]-1,
5-naphthyridine tetraphosphate. It is a derivative of benzon-
aphthyridine, with a side chain similar to amodiaquine and
has both acidic and basic functional groups [5]. PNDP is
a blood schizonticidal drug active against the erythrocytic
stages of the malarial parasite and has already undergone
limitedtrialsinhumansagainstbothPlasmodiumfalciparum
and Plasmodium vivax [6]. Preliminary clinical studies
conducted in China have demonstrated its safety and eﬃcacy
against the malarial parasites [7]. Pyronaridine tetraphos-
phate is also reported to be eﬀective against chloroquine and
multi-drug-resistant Plasmodium falciparum malaria [8]. It
is reported to be less toxic than chloroquine and highly
eﬀective against chloroquine-sensitive and resistant parasites
both in rodent malarias in vivo and Plasmodium falciparum
in vitro [9]. Clinical studies carried out in Thailand [10]a n d
in Cameroon [11] have reported that oral administration
of PNDP is well tolerated and eﬀective against falciparum
malaria. In spite of its clinical eﬃcacy being documented by
several investigators, its pharmacological action still remains
unclear. Studies have shown that PNDP aﬀects haemoglobin
degradation, possibly through an eﬀect on the parasite
topoisomerase II [12] and also by inhibiting P-glycoprotein
mediated multidrug resistance [13]. Auparakkitanon et al.
[14] have shown that pyronaridine targets hematin and
inhibits in vitro beta-hematin formation (at a concentration
equal to that of chloroquine), by forming a complex
with hematin with a stoichiometry of 1:2, to enhance
hematin-induced red blood cell lysis (but at 1/100 of the
chloroquine concentration) and also inhibits glutathione-
dependent degradation of hematin.
The present investigation was designed to study and
characterize the absorption, distribution, excretion, and
pharmacokineticsof 14C-PNDPinmaleandfemaleSprague-
Dawley rats for a period of 10 days, following administration
of a single target dose of 10mg/kg.
2.MaterialsandMethods
2.1. Chemicals. Pyronaridine base was supplied by Shin
Poong Pharmaceuticals Co., Ltd. Seoul, Republic of Korea.
Pyronaridine tetraphosphate (PNDP) and 14C-pyronaridine
tetraphosphate (14C-PNDP) were synthesized at KAERI
laboratory. 14C-PNDP (Figure 1(b)) had a radiochemical
purity >98% and speciﬁc activity >10µCi/mg which was
checked according to previously reported method [15]. All
other chemicals were purchased from Sigma Chemical Co.,
St. Louis, USA.
2.2. Animals. Male and female Sprague-Dawley rats were
obtained from Central Lab Animal Inc., Seoul, Republic of
Korea and weighed 150–200g on the day of dosing. Within a
study, the individual body weights were within ±10 standard
deviations from the mean body weight of each sex and
group mean body weights for each group of each sex were
not statistically diﬀerent at the 5% probability level. Rats
were divided in 10 groups with 6 animals in each group
corresponding to the time intervals at which the samples
were analyzed. The animals were housed in polypropylene
cages before and after dosing and were provided with a
certiﬁed rodent pellet diet and pure drinking water. Animals
weremaintainedundercontrolledconditionsoftemperature
(22±2◦C), relative humidity (55±5%) and approximately 12
hours light and dark cycle. For excretion studies, male and
femaleSprague-Dawleyratswerehousedinglassmetabolism
cages (Tecniplast, Italy). All the animal experiments were
performed in compliance with the guidelines prescribed by
the institutional animal ethical committee.
2.3. Dose Preparation. 14C-PNDP (radiochemical purity
>98%) was orally administered to male and female Sprague-
Dawley rats at a dose of 10mg/kg b·w (2.07MBq/animal)
in 0.4% methylcellulose prepared in saline. Rats were fasted
over night before the administration of dose and also
for approximately 4 hours postdosing. The target dose of
10mg/kgb·w was administered by a single oral gavage using
a ball tipped needle. All doses were freshly prepared on
the day of dosing and administered within 4 hours of
preparation.
2.4. Blood Collection and Plasma Separation. Post admin-
istration of 14C-PNDP, blood (approximately 1mL) was
collected from each rat via a cannula placed in the jugularJournal of Biomedicine and Biotechnology 3
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Figure 1: (a) Structure of pyronaridine tetraphosphate (PNDP).
(b) Structure of 14C-pyronaridine tetraphosphate (14C-PNDP).
vein at time intervals of 1, 4, 8, 24, 48, 96, 144, 192,
and 240 hours after administration of the drug. Whole
blood from each animal was collected in 2 separate vials
with and without heparin. Plasma was collected from the
blood collected in heparinized tubes by centrifugation at
3000rpm for 15 minutes and stored in separate vials at 4◦C
until analysis. The whole blood (collected without heparin)
and plasma samples obtained from each rat from both
genders were mixed with appropriate volumes of Hionic-
Fluor scintillation cocktail and tested for radioactivity using
Liquid Scintillation Counter (LSC) (TRI-CARBTM 1600TR,
Packard, USA). Although, PNDP has a good stability for
up to 4 weeks in refrigerated and frozen whole blood
samples [16], in this study all the samples were analyzed
for radioactivity within 48 hours of sample collection, until
which they were stored at 4◦C.
2.5. Biodistribution Studies. Following collection of blood
samples, the animals were killed by halothane anesthesia
at time intervals of 1, 4, 8, 24, 48, 96, 144, 192, and
240 hours postdosing and selected tissues, namely, liver,
heart, lung, brain, spleen, kidney, stomach, small and large
intestines were removed, rinsed in ice-cold saline and blotted
to dryness. The tissues were then weighed and stored at
−20◦C until further analysis. The tissues were digested using
solvable (Packard Bioscience, CT, USA) and mixed with
0.5mL of methanol to prevent precipitation. Appropriate
volumes of Hionic-Fluor scintillation cocktail were added
andthenanalyzedbyLSCforradioactivity.Aftertheremoval
of selected tissues, the carcass was digested by submerging
the entire rat in 500mL of 6N potassium hydroxide solution.
Aliquots (0.5mL) of each rat carcass homogenate were
mixed with 0.5mL of methanol to prevent precipitation.
Appropriate volumes of Hionic-Fluor scintillation cocktail
were added to the samples and they were counted for
radioactivityLSC.Allsampleswereanalyzedforradioactivity
within 48 hours of collection and processing.
2.6. Mass Balance/Excretion Studies. For mass balance
/excretion studies, animals were placed in glass metabolic
cages after the administration of a target dose of 14C-PNDP.
Urine was collected in glass containers containing 10%
H3PO4 (about 1mL) at time intervals of 0−4, 4−24, 24−48,
48−72, 72−96, 96−120, 120−144, 144−168, 168−192,
192−216,and216−240hourspostdosing.Theurinesamples
were stored at 4◦C until further analysis. They were mixed
with Hionic-Fluor liquid scintillation cocktail and analyzed
by LSC for the detection of radioactivity. The feces were
also collected in the same manner at same time intervals
as mentioned above. The feces was then homogenized
with water (1:3) using a homogenizer and oxidized using
Packard TRICARB Oxidizer. The residues were mixed with
appropriate volumes of Hionic-Fluor scintillation cocktail
and analyzed by LSC. After the last excreta collection, the
cages were washed with about 400mL of 1% trisodium
phosphate and wiped with gauze pads. The cage wash was
also collected into plastic containers, containing 12mL of
10% H3PO4. The cage wash was mixed with appropriate
volumes of Hionic-Fluor scintillation cocktail and analyzed
by LSC.
2.7. 14CO2 Breath Test. To determine the amount of drug
excreted in breath the animals were placed in specialized
cages that were attached to a carbon dioxide analyzer
(CAPSTAR-100)ﬁttedwithapump(LeticaROxilet4LE400-
4) which regulated the ﬂow of air in and out of the cages.
Animals were maintained under controlled conditions of
temperature (22±2◦C), relative humidity (55±5%), and
approximately12hourslightanddarkcycle.Maleandfemale
Sprague-Dawley rats were administered the target dose of
10mg/kg b·wo f14C-PNDP and were placed in specialized
polypropylene cages where the air ﬂow was tightly regulated
as explained above. The expired air from the cage was
bubbled through a solution of sodium hydroxide (1M) to
trap the 14CO2. OnemL of the trapping solution (NaOH)
was collected at time intervals of 1, 4, 8, 24, 48, 96, 144, 192,
and 240 hours postdosing and stored in vials until further4 Journal of Biomedicine and Biotechnology
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Figure 2: Mean plasma concentration-time proﬁles in male and
female Sprague-Dawley rats after administration of a single oral
dose of 10mg/kg of 14C-PNDP (n = 6, Mean±S.D.).
analysis. The aliquots were then mixed with appropriate
volumes of Hionic-Fluor scintillation cocktail and analyzed
by LSC.
3. Results
The results of absorption, distribution, excretion, and phar-
macokinetic of 14C-PNDP in male and female Sprague-
Dawley rats following a single oral administration are
presented hereunder.
3.1. Biodistribution of 14C-PNDP in Blood and Plasma. 14C-
PNDP was quickly absorbed and delivered and was present
in measurable levels throughout the entire body following
oral administration. It was observed that 14C-PNDP can
easily pass through a number of compartments to reach
targets around the whole body. This was evident by the
observedradioactivityinthebloodandplasmawithin1hour
of dosing. The distribution of 14C-PNDP was found to be
almost similar across both genders of Sprague-Dawley rats.
The mean plasma Cmax of 14C-PNDP was 207.2µg/mL in
male rats and 189.2µg/mL in female rats. Corresponding
blood Cmax values for 14C-PNDP were 222.8µg/mL in male
ratsand220.6µg/mLinfemalerats.Theareaunderthecurve
(AUC) in plasma was 14.1 and 14.7µg·h/mL in male and
female rats, whereas in blood it was 25.0 and 23.1µg·h/mL
in male and female rats, respectively (Table 1; Figures 2 and
3).
3.2. Biodistribution of 14C-PNDP in Tissues. 14C-PNDP was
rapidly adsorbed mainly from the small intestine than from
stomach following oral administration and it was rapidly
distributed in most of the tissues studied which is evidenced
by the observed radioactivity in all the tissues studied within
1hourofdrugadministration.TheCmax inthestomach(47.9
0
50
100
150
200
250
300
C
o
n
c
e
n
t
r
a
t
i
o
n
(
n
g
e
q
u
i
v
/
m
L
)
1 4 8 24 48 96 144 192 240
Female
Male
Figure 3: Mean blood concentration-time proﬁles in male and
female Sprague-Dawley rats after administration of a single oral
dose of 10mg/kg of 14C-PNDP (n = 6, Mean±S.D.).
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Figure 4: Mean concentrations of radioactivity/g tissue in male
Sprague-Dawley rats after administration of a single oral dose of
10mg/kg of 14C-PNDP (n = 6, Mean±S.D.).
and 30.7µgeq/g) was reached in 1 hour in both male and
female rats, while in small intestine (166.3 and 186.1µgeq/g)
it was observed after 2 hours in male rats and 4 hours in
female rats. The drug was rapidly distributed to various
organs with the Cmax in the liver (186.8 and 189.8µgeq/g)
being observed by 4.7 hours both in male and female rats.
The Cmax in kidney (53.6 and 31.0µgeq/g), heart (10.1 and
7.9µgeq/g) and lungs (36.4 and 41.9µgeq/g) was reached
in 7−10 hours in both male and female rats. The Cmax in
spleen (88.0 and 76.6µgeq/g) was reached in 21 hours and
in brain (6.7 and 8.2µgeq/g) it was in about 36 hours. The
low levels of radioactivity observed in the brain indicate that
14C-PNDP diﬀuses poorly through the blood-brain barrier.
The radioactivity in all the tissues gradually decreased to lessJournal of Biomedicine and Biotechnology 5
Table 1: Plasma and blood pharmacokinetic parameters in male and female Sprague-Dawley rats after administration of a single oral dose
of 10mg/kg of 14C-PNDP (mean±SD, n = 6).
Cmax Tmax t1/2 AUC240hr AUCinf
(ng/mL) (hr) (hr) (µg·hr/mL) (µg·hr/mL)
Male SD-rat Plasma 207.2 ±31.97 .3 ±1.6 148.5 ±39.11 4 .1 ±1.52 1 .4 ±4.0
Whole blood 222.8 ±20.91 0 .7 ±6.5 138.1 ±52.72 5 .0 ±1.83 5 .6 ±5.4
Female SD-rat Plasma 189.2 ±48.48 .0 ±0.0 157.5 ±30.31 4 .7 ±1.12 3 .1 ±2.3
Whole blood 220.6 ±21.08 .0 ±0.0 211. ±51.72 3 .1 ±2.83 8 .8 ±3.7
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Figure 5: Mean concentrations of radioactivity/g tissue in female
Sprague-Dawley rats after administration of a single oral dose of
10mg/kg of 14C-PNDP (n = 6, Mean±S.D.).
than 30µgeq/g post 48 hours of drug administration (Tables
2 and 3, Figures 4 and 5).
3.3. Mass Balance/Excretion of 14C-PNDP. The main route
of excretion for 14C-PNDP was through the urine followed
by fecal excretion. About 47% (49.9% in males and 47.6%
in females) of the drug were excreted in the urine, whereas
excretion of the drug in feces accounted for only about 5-6%
of the total drug administered. Radioactivity was observed
in urine and feces from 4 hours postdosing. The rate of
excretion via urine peaked by 24 hours and thereafter it
remained constant with no further decrease (Table 4, Figures
6 and 7).
3.4. 14CO2 Breath Test. 14C-PNDP was also excreted in the
breath as 14CO2. The rate of excretion was minimal for
up to 8 hours and it peaked by 24 hours and thereafter
there was a gradual increase in the radioactivity until 240
hours. There was no gender diﬀerence observed with respect
to the excretion of the drug in the breath. The carcass
also contained a moderate amount of radioactivity at 240
hours postdosing, and it accounted for about 7.7% of the
radioactive dose (Figure 8).
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Figure 6: Cumulative activity excretion proﬁle in the urine and
feces of male Sprague-Dawley rats at diﬀerent time period after
administration of a single oral dose of 10mg/kg of 14C-PNDP (n =
6, Mean±S.D.).
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Figure 7: Cumulative activity excretion proﬁle in the urine and
feces of female Sprague-Dawley rats at diﬀerent time period after
administration of a single oral dose of 10mg/kg of 14C-PNDP (n =
6, Mean±S.D.).
4. Discussion
The control of malaria has been severely compromised by
the development of malaria parasites resistant, particularly
in Plasmodium falciparum to nearly all available antimalarial6 Journal of Biomedicine and Biotechnology
Table 2:TissuepharmacokineticparametersinmaleSprague-Dawleyratsafteradministrationofasingleoraldoseof10mg/kgof 14C-PNDP
(n = 6, Mean±S.D.).
Tissues Cmax Tmax t1/2 AUC240hr AUCinf
(µg/g) (hr) (hr) (µg·hr/g) (µg·hr/g)
Brain 6.7 ±1.83 1 .3 ±6.5 160.2 ±165.37 8 .1 ±15.4 171.2 ±65.5
Lung 36.4 ±4.61 0 .7 ±6.5 109.0 ±19.7 2573.6 ±201.9 3006.6 ±246.2
Heart 10.1 ±1.51 0 .7 ±6.5 200.6 ±37.9 713.8 ±104.3 901.6 ±170.4
Liver 186.8 ±18.94 .7 ±1.6 216.4 ±46.8 4167.5 ±557.3 8107.2 ±969.1
Spleen 88.0 ±14.94 4 .0 ±49.0 125.7 ±30.3 1005.3 ±224.1 1367.7 ±334.7
Kidney 53.6 ±12.72 1 .3 ±6.5 111.8 ±17.9 441.6 ±44.2 557.3 ±94.8
Stomach 47.9 ±13.61 .0 ±0.0 129.1 ±37.1 535.3 ±12.8 700.9 ±62.5
Small intestine 166.3 ±15.52 .0 ±1.5 142.6 ±73.6 2181.8 ±251.3 2532.7 ±505.5
Large intestine 17.5 ±4.71 6 .0 ±8.8 105.0 ±29.8 1063.8 ±83.5 1265.6 ±94.9
Table 3: Tissue pharmacokinetic parameters in female Sprague-Dawley rats after administration of a single oral dose of 10mg/kg of 14C-
PNDP (n = 6, Mean±S.D.).
Tissues Cmax Tmax t1/2 AUC240hr AUCinf
(µg/g) (hr) (hr) (µg·hr/g) (µg·hr/g)
Brain 8.2 ±2.73 6 .7 ±28.4 184.3 ±111.2 107.1 ±22.5 176.5 ±28.9
Lung 41.9 ±5.48 .0 ±0.0 120.3 ±26.9 3033.5 ±324.6 4123.0 ±400.3
Heart 7.9 ±1.07 .3 ±1.6 198.5 ±53.9 700.6 ±147.8 1267.9 ±279.8
Liver 189.8 ±8.14 .7 ±1.6 218.4 ±74.0 4919.1 ±342.2 8887.8 ±894.9
Spleen 76.6 ±7.04 2 .3 ±5.6 118.9 ±55.1 1257.6 ±509.9 2483.6 ±536.8
Kidney 31.0 ±2.88 .0 ±1.2 144.2 ±17.5 372.5 ±20.9 572.3 ±60.9
Stomach 30.7 ±11.81 .0 ±0.4 127.0 ±27.9 623.2 ±46.5 835.6 ±49.7
Small intestine 186.1 ±12.24 .0 ±1.2 166.6 ±16.3 3479.4 ±173.6 3793.5 ±309.8
Large intestine 23.9 ±2.81 8 .0 ±2.39 9 .8 ±29.6 1556.5 ±125.6 2078.4 ±539.9
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Figure 8: Excretion of 14CO2 in the breath of male and female
Sprague-Dawley rats at diﬀerent time period after administration
of a single oral dose of 10mg/kg of 14C-PNDP (n = 6, Mean±S.D.).
drugs used for prophylaxis and treatment [17]. The world-
wide spread of strains of Plasmodium that are resistant
to chloroquine and the serious side-eﬀects encountered
on using the newer drugs have highlighted the urgent
need for developing new antimalarial drugs. Pyronaridine
tetraphosphate, a benzonaphthyridine derivative, has been
in use in China for more than 10 years for the treatment of
malaria. It is a Mannich base which is reported to exhibit
antimalarial blood schizonticidal activity and is currently
under investigation for use in the chemotherapy of malaria.
Although the eﬀect of pyronaridine on the ultrastructure
of malaria parasite has been reported [18], studies on its
absorption, distribution, and excretion in rodents have not
been previously reported. Lee et al. [19] have reported that
in vitro incubation of pyronaridine with rat and human
livermicrosomesresultedintheformationof11metabolites,
with pyronaridine quinoneimine as the major metabolite.
The synthesis of 14C-PNDP by classical method and also by
microwave irradiation technique has been earlier reported
[15].
In the present investigation, the absorption of 14C-
PNDP after a single oral dose administration followed by
its distribution in various tissues like blood, plasma, liver,
lung, heart, spleen, kidney, brain, stomach, small intestine
and large intestine and its excretion in urine, feces and
in breath as 14CO2 were determined in male and female
Sprague-Dawley rats for 10 days. After oral administration,
close and regular visual monitoring of the animals revealed
that there were no severe acute toxicity responses as none of
the animals showed any signs of behavioral or neurological
toxicity during the entire study period. The results indicateJournal of Biomedicine and Biotechnology 7
Table 4: Mean percentage cumulative recovery of total radioactivity over 240 hours post administration of a single oral dose of 10mg/kg of
14C-PNDP.
Mean percentage radioactive dose
Male SD-rat (%) Female SD-rat (%)
Faeces 5.0 ±0.76 .5 ±1.6
Urine 49.9 ±3.54 7 .6 ±6.2
Cage rinse 0.5 ±0.10 .4 ±0.1
CO2 1.0 ±0.21 .1 ±0.1
Carcass 12.7 ±1.01 3 .1 ±2.0
Tissues 17.1 ±1.51 8 .9 ±1.2
Blood 13.2 ±1.31 2 .2 ±1.1
Total 99.4 ±2.99 9 .8 ±2.5
that the drug is readily absorbed from the small intestine
within 1 hour following oral administration and was widely
distributed in most of the tissues investigated as determined
from the observed radioactivity in the tissues. Peak value of
the drug in the blood was reached at around 8 hours post
administration and radioactivity was detected in most of
the tissues from 4 hours onwards. 14C-PNDP showed poor
permeability across the blood-brain barrier characterized by
low levels of radioactivity in the brain tissue. It was observed
that the Tmax in the liver was earlier than that of blood,
indicating a faster absorption of the drug from the intestine
and rapid transport to the liver. The overall absorption,
distribution, and excretion of 14C-PNDP were found to be
gender-independent as both male and female rats showed a
similar pattern of radioactivity. Excretion of the drug was
predominantly through the urine which started around 10
hours post administration and peak excretion was observed
from 24 hours onwards. A small amount of the drug was also
excreted in the feces and also in the breath.
Phase II clinical trials on the pharmacokinetics, clinical
and safety outcome of Pyramax (pyronaridine/artesunate)
carried out in 16 patients in Uganda with acute falciparum
malaria revealed that Pyramax was well tolerated and
showed a very pronounced distribution and elimination
phase [20]. The Cmax values in patients receiving pyronari-
dine/artesunate (12 + 4mg/Kg once a day for 3 days) were
226.1±157.5ng/mL which is close to those found in rats in
this study. The t1/2 of 14C-PNDP in this study was found to
be signiﬁcantly lower compared with that of Phase II clinical
trials which is possibly due the multiple dose regimens.
Administration of a single dose of 14C-PNDP resulted in
the AUC (0-inf) and Tmax values which were almost similar
to those observed in Phase II clinical trial data. The slight
variation in these values can be explained by the fact that
multiple dose regimens (once a day for 3 days) were used in
the clinical trials whereas in the present investigation the rats
were administred with only a single dose of 14C-PNDP.
The life cycle of the malarial parasites in the human
host occurs mainly in the blood and liver and hence, they
are considered to be the main targets of any antimalarial
drug. The result of the study shows that 14C-PNDP is
rapidly absorbed and distributed in the tissues and the
drug was mainly concentrated in the liver and blood
than other organs which is evident by the high Cmax
and t1/2. The rapid absorption and slow elimination of
PNDP from the target organs might provide eﬀective
antimalarial activity to the drug. According to the WHO,
all uncomplicated P. falciparum infections should be
treated with an artemisinin-based combination therapy and
currently there are four ACTs that are recommended for
use in the treatment of malaria: artemether-lumefantrine,
artesunate-amodiaquine, artesunate-meﬂoquine and
artesunate-sulfadoxine-pyrimethamine. The choice of ACT
is based on the eﬃcacy of the partner medicine in the
country or area of intended deployment [1]. Although
artemisinins are potent and rapidly acting antimalarial
drugs, their widespread use for treating patients with
Plasmodium falciparum malaria raises the question of
emerging drug resistance [21, 22]. A recent study conducted
along the Thai-Cambodian border reports of high failure
rates associated with ACT, as well as in vitro drug-
susceptibility data, suggesting the possibility of clinical
artemisinin resistance [23, 24]. Based on their study, Noedl
et al. [25] reported that although artemisinin resistance does
not seem to be a widespread epidemiologic phenomenon
currently, the prolonged parasite-clearance times during
artesunate therapy are a matter of concern. These factors
underscore the need for the development of improved ACTs
and a better understanding of the pharmacokinetics and
mechanism of action of the components of ACTs. In such
a scenario, pyronaridine tetraphosphate is being further
explored for its use in the treatment of malaria either alone
or in combination with artemisinin. With Phase II and a
controlled Phase III [26, 27] clinical trial on Pyramax of
which pyronaridine is a major component showing positive
results, its is believed that Pyramax will be available for
treating both falciparum and vivax malaria by 2010 in Asia
and Africa.
5. Conclusion
The results of the investigation showed that PNDP was
readily absorbed and distributed to the tissues following
an oral administration. The drug was well tolerated and8 Journal of Biomedicine and Biotechnology
eﬀectively eliminated in the urine. Phase II and a controlled
Phase III clinical trial on Pyramax of which pyronaridine
is a major component has shown positive results. With
resistance being reported for ACTs, pyronaridine tetraphos-
phate seems to be a promising candidate for developing new
ACTs.
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